Navigation Links
Greenphire CEO Sam Whitaker speaks on Sunshine Act and Clinical Trial Payments
Date:12/4/2012

KING OF PRUSSIA, Pa., Dec. 4, 2012 /PRNewswire-iReach/ -- Greenphire CEO Sam Whitaker spoke at the Sunshine Act and Aggregate Spend Bootcamp on the implications of the Physician Sunshine Act for the management of clinical trial payments and on advances in technology which streamlines financial reporting required to comply with the Act. 

The discussion focused on how pharmaceutical, biotech, and medical device companies can use technology to gather and report on required data on clinical trial payments, which present a particular tracking challenge because each clinical trial may involve a complex series of payments made to multiple physician investigators across multiple clinical sites.  To further complicate matters, payments may be made directly or by third parties like Contract Research Organizations (CROs).  Sam's discussion also focused on best practices in preparing for the Act and on the ancillary benefits to sponsor organizations of implementing data aggregation technologies across clinical trials, which include increased automation, tracking, and accountability, and reduced costs and risk.

The presentation took place on Tuesday, December 4, 2012 in Philadelphia, PA.  The Sunshine and Aggregate Spend Bootcamp is an intensive, hands-on seminar intended to prepare pharmaceutical and medical device companies for the requirements of complying with aggregate spend reporting under the Physician Sunshine Act.

About Greenphire

Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

Media Contact: Shana Jalbert Greenphire, (215) 948-9260, shana.jalbert@greenphire.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Greenphire
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Autism Speaks announces the release of new genetic data for researchers
2. Autism Speaks and SAGE® Labs develop rat models for translational autism research
3. Autism Speaks awards nearly $2.9 million to fund autism research
4. Autism Speaks awards $1.1 million to fund high priority studies
5. Plant DNA speaks English, identifies new species
6. Sunshine, biofuel and the tides, oh my!
7. TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
8. Clinical hypnosis can reduce hot flashes after menopause, Baylor study shows
9. BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
10. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
11. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology: